pemigatinib (Pemazyre) Report issue

Small molecule Orphan Drug FDA Approved FDA Breakthrough Therapy FDA Accelerated Approval FDA Priority Review FDA
AACT
Back

Drug Pricing Summary

VA Big4

$908.9450

VA FSS

$1195.9800

Drug Product Pricing

Product $/unit Ctry. List Type
Product (units) Manufacturer
pemigatinib 13.5 mg (TABLET) $908.9450 VA Big4
  • PEMAZYRE (14)
    		•  Incyte Corporation
    pemigatinib 13.5 mg (TABLET) $1195.9800 VA FSS
  • PEMAZYRE (14)
    		•  Incyte Corporation
    pemigatinib 4.5 mg (TABLET) $908.9450 VA Big4
  • PEMAZYRE (14)
    		•  Incyte Corporation
    pemigatinib 4.5 mg (TABLET) $1195.9800 VA FSS
  • PEMAZYRE (14)
    		•  Incyte Corporation
    pemigatinib 9 mg (TABLET) $908.9450 VA Big4
  • PEMAZYRE (14)
    		•  Incyte Corporation
    pemigatinib 9 mg (TABLET) $1195.9800 VA FSS
  • PEMAZYRE (14)
    		•  Incyte Corporation

    Note: This drug pricing data is preliminary, incomplete, and may contain errors.

    Feedback

    Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

    Report issue